Pregnancy is associated with hemostatic challenges that may lead to thrombosis.
Introduction
Thrombotic lesions in the placenta are commonly associated with major complications of pregnancy, such as pre-eclampsia, stillbirth, fetal growth retardation, preterm labor, and preterm rupture of membranes [1] [2] [3] [4] [5] [6] [7] . Exchange of blood gases and nutrients occurs at the level of placental villi, which consist of branched fetal blood vessels covered by a layer of syncytiotrophoblasts. Maternal blood circulates in the spaces between the villi. Although a low level of fibrin deposition localized to areas of denudation of the syncytiotrophoblast layer can be detected in normal placentas at term 8 , larger fibrin deposits may occur in the intervillous space or in the fetal blood vessels and compromise placental function 9 . Thrombin converts fibrinogen to fibrin and must be tightly regulated to prevent placental thrombosis.
Antithrombin and heparin cofactor II (HCII) are glycosaminoglycan (GAG)-dependent thrombin inhibitors found in both maternal and fetal plasma 10 . Antithrombin inhibits thrombin rapidly when bound to heparin or heparan sulfate (HS), while HCII is activated by dermatan sulfate (DS) in addition to heparin and HS 11 . Antithrombin deficiency is a well established risk factor for venous thromboembolism and may increase the incidence of fetal loss ~1.7-fold 12 . The physiologic role of HCII remains unclear, although above average levels of HCII are reported to be associated with decreased prevalence of carotid artery atherosclerosis 13 and in-stent re-stenosis 14, 15 .
Indirect evidence suggests that HCII activity increases during pregnancy. During the third trimester, plasma HCII levels are approximately 140% of normal [16] [17] [18] , and thrombin-HCII complexes are elevated up to 4-fold 19 . At the same time, both maternal and fetal plasma contain trace amounts of a DS proteoglycan that stimulates thrombin 20 . The placenta is rich in DS 21 and may be the source of this proteoglycan. In one study, a DS proteoglycan (decorin) was purified from human placenta and was shown to have HCII-dependent anticoagulant activity 22 . Interestingly, HCII levels are only ~50% of normal in women with severe pre-eclampsia 16 , suggesting an association between decreased HCII activity and placental dysfunction.
In the present work, we isolated DS from human term placenta and characterized its sulfation pattern. We also performed immunohistochemical analyses to determine the location of DS and HCII in the normal term placenta. Our findings suggest that HCII and DS are positioned to interact with one another and inhibit thrombin at sites of villous injury. compound was from Sakura, Tokyo, Japan.
Materials and Methods

Reagents
Isolation of placental GAGs -Approval for this study was obtained from the Human Studies Committee of Washington University Medical School. Informed consent was provided according the the Declaration of Helsinki. Placentas were obtained from women with uncomplicated pregnancies after vaginal delivery and were kept on ice until being processed (<1 hour). Maternal decidua, fetal membranes, and visible blood vessels were removed. The remaining tissue was cut into fine pieces and rinsed several times with ice-cold phosphate buffered saline (PBS). The minced tissue was then homogenized in a blender after adding a small volume of PBS. Approximately 250 g (40 g dry weight determined by lyophilization) of homogenized material was suspended in 0.5 L of 0.1 M sodium acetate buffer (pH 5.5) containing 25 g of crude papain, 5 mM EDTA and 5 mM cysteine, and was incubated at 60 °C for 24 h. The incubation was then centrifuged at 2000 × g for 10 min at 4 °C. The supernatant was collected and saved at 4 °C, while the precipitate was digested for another 24 h as described above. The clear supernatants from the two digests were combined, and the polysaccharides were precipitated with 250 ml of 50 mg/mL cetylpyridinium chloride for 1 h at 37°C. The mixture was then centrifuged at 26 . Porcine mucosal DS was also digested with chondroitin ABC-lyase as described above, and its disaccharide composition was determined.
Anticoagulant activity assays -Human HCII and antithrombin were purified as previously described 27 . Placental GAGs at various steps of purification were tested for the ability to stimulate thrombin inhibition by HCII as follows: 10 µL of HCII (50 µg/mL), 10 µL of the GAG, and 10 nM human -thrombin were mixed in a 1.5-mL semimicro cuvette in a total volume of 100 µL of buffer containing 50 mM Tris-HCl, 150 mM NaCl, and 1 mg/mL polyethylene glycol 8000, pH 7.4 (TS/PEG buffer). Thrombin was added last to initiate the reaction. After a 60-s incubation at room temperature, 500 µL of 100 mM tosyl-Gly-Pro-Arg-p-nitroanilide in TS/PEG buffer was added, and the absorbance at 405 nm was determined continuously for 100 seconds. The rate of change of absorbance was proportional to the concentration of active thrombin that remained in the incubation. The assay was calibrated with known amounts (0-2 µg) of porcine mucosal DS. To determine the ability of GAGs to stimulate thrombin inhibition by antithrombin, 10 µl of antithrombin (28 µg/mL) was substituted for HCII, and the assay was calibrated with bovine lung heparin.
Preparation of placental tissue sections -Small blocks of placental tissue were rinsed several times with ice-cold PBS. For the preparation of frozen sections, the tissue was embedded in Tissue-Tek OCT compound, frozen on dry ice, and stored at -70 °C.
For paraffin blocks, the tissues were fixed for 48 h in 10% buffered neutral formalin, pH Antibody staining of GAGs -To determine the location of GAG chains in placental sections, we used monoclonal antibodies that detect the "stubs" remaining after digestion with various lyases 28, 29 . Unfixed frozen sections were incubated for 2 h at 37 sections were developed using avidin:biotinylated peroxidase complex and 3,3'-diaminobenzidine as described above and were examined by light microscopy as described in the preceding section.
Results
Isolation of placental GAGs -Extraction of 40 g (dry weight) of human placental tissue with papain yielded 171 mg of total GAGs ( Table 1) . The GAGs were then applied to a Mono Q anion-exchange column and step-eluted with 0.25 M, 0.8 M, and 2.0 M NaCl, yielding three peaks (I, II, and III) as shown in Fig. 1 
. The material in
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Peaks II and III were pooled separately and then treated sequentially with nitrous acid to degrade HS, with chondroitin AC II-lyase to degrade chondroitin 4-sulfate (C4S) and chondroitin 6-sulfate (C6S), and finally with chondroitin ABC-lyase to degrade DS (substrate specificities summarized in Table 2 ). The total amount of GAG recovered after each treatment is indicated in Table 1 . Based on these data, peak II contained 35% HS, 16% C4S and/or C6S, 17% DS, and 32% other uronic acid-containing material (e.g., hyaluronic acid). Peak III contained 14% HS, 59% C4S and/or C6S, 26% DS, and 1% other material. The composition of peak III was confirmed by agarose gel electrophoresis. Most of the material in this peak co-migrated with DS and CS standards (Fig. 2, panel A) . Little or no material was detectable in the vicinity of a HS standard, but this standard stained relatively poorly with toluidine blue. Treatment of peak III with nitrous acid did not alter the appearance of the stained gel, whereas treatment with chondroitin AC II-lyase left a single band that co-migrated with DS (Fig. 2, panel B) .
Treatment with chondroitin ABC-lyase, which cleaves both CS and DS, degraded virtually all of the material in peak III.
Anticoagulant activity of GAG fractions -The papain extract stimulated thrombin inhibition by HCII with a specific activity of 0.196 relative to that of porcine mucosal DS. Thus, the total activity of the papain extract was equivalent to that of 33.5 mg of porcine mucosal DS (Table 1) . About 93% of the activity eluted from the Mono Q column with 2 M NaCl (peak III), and most of the activity in peak III was resistant to treatment with nitrous acid and chondroitin AC II-lyase but was sensitive to treatment with chondroitin ABC-lyase. Thus, HCII is stimulated by a highly-charged DS fraction of the placental extract. The specific activity of the final product was 1.30 
mucosal DS, and the yield was 74%. Only about 1% of the HCII-stimulating activity was present in peak II. None of the three Mono Q fractions stimulated thrombin inhibition by antithrombin to a significant degree.
Disaccharide analysis of placental DS -The DS from peak III that remained after treatment with nitrous acid and chondroitin AC II-lyase was dialyzed and then digested with chondroitin ABC-lyase. The resulting disaccharides were analyzed by strong anion-exchange chromatography (Fig. 3 and Table 3 
Immunohistochemical localization of DS in the placenta -Unfixed frozen
sections of placenta were treated with chondroitin B-lyase, AC II-lyase, or ABC-lyase, which cleave the glycosidic linkages between hexosamine and hexuronic acid, leaving behind oligosaccharide "stubs" with 4,5 -hexuronic acid (unsaturated) residues at the nonreducing termini. The sections were then stained with an antibody ( Di-4S) that recognizes the 4,5 -hexuronic acid N-acetylgalactosamine 4-sulfate disaccharide. Blood vessels and stroma of the placental villi were strongly stained after treatment with chondroitin ABC-lyase, which digests DS, C4S and C6S, or with chondroitin B-lyase, which specifically digests DS (Fig. 4, panels A and B) . Weaker staining of the same structures was observed after treatment with chondroitin AC II-lyase, which digests C4S and C6S, but not DS (Fig. 4, panel C) . Syncytiotrophoblast cells did not stain after treatment with any of these three lyases. Little or no staining with Di-4S antibody was observed in sections that had not been treated with enzyme (Fig. 4, panel D) . Sections
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From were also treated with Flavobacterium heparitinase, which cleaves HS chains to yield 4, 5 -hexuronic acid at the nonreducing termini. These sections were stained with an antibody ( -HS) that recognizes the unsaturated hexuronic acid. In contrast to the results obtained with chondroitin B-lyase, syncytiotrophoblasts were strongly stained after heparitinase treatment; staining of villous stromal regions and blood vessels was also observed (Fig. 4, panel E) . Minimal background staining with -HS antibody was observed in sections that had not been treated with heparitinase (Fig. 4, panel F) .
Immunohistochemical localization of endogenous HCII in the placentaFormalin-fixed human placental sections were stained with goat anti-HCII IgG or nonimmune IgG as a control. HCII was detected in the walls of the villous blood vessels and in the syncytiotrophoblast cell layer (Fig. 5) . Relatively little HCII was detectable in the villous stroma.
Discussion
HCII is unique among thrombin inhibitors with regard to its ability to be stimulated by DS 11 . DS is a linear polysaccharide found on cellular membranes and in Fractionation of placental GAGs yielded a highly-charged DS fraction capable of stimulating thrombin inhibition by HCII. The final product (Mono Q peak III treated with nitrous acid and chondroitin AC II-lyase) co-migrated with standard DS on gel electrophoresis and retained 74% of the total HCII stimulating activity of the initial papain extract. Chondroitin AC II-lyase, however, may cleave some linkages in DS that contain glucuronic acid residues. Therefore, the DS polymers obtained after treatment with this enzyme may have an average molecular weight lower than that of the native polysaccharide. Since the molecular weight affects the anticoagulant activity of DS 35 , the value of HCII activity reported in Table 1 for Mono Q peak III after AC II-lyase treatment is a minimum estimate. The activity was entirely abolished by treatment with chondroitin ABC-lyase, which degrades DS. Although Mono Q peaks II and III both contained significant amounts of HS, peak II had almost no activity with HCII and peak III retained activity after treatment with nitrous acid. Therefore, placental HS does not appear to be capable of activating HCII. Since none of the material in Mono Q peaks I, II, or III stimulated thrombin inhibition by antithrombin in vitro, we conclude that DS is the predominant anticoagulant GAG in the placenta.
The disaccharide composition of peak III DS was comparable to that of DS derived from porcine skin or intestinal mucosa, which contain 5-11% of the disulfated disaccharides previously implicated in binding to HCII [31] [32] [33] [34] . Immunohistochemical experiments indicated that DS is associated with the walls of fetal blood vessels and the villous stroma but is notably absent in the syncytiotrophoblast layer. In agreement with this finding, a previous study found that the core protein of the DS proteoglycan decorin is present in the villous stroma but is absent in trophoblasts 36 . These observations suggest that HCII in maternal blood would come in contact with DS only after injury to syncytiotrophoblasts covering the surface of placental villi. Since fibrin deposits have been shown to occur in regions of syncytiotrophoblast loss 8 , HCII might serve to limit coagulation at such sites of injury.
The pathologic features of pre-eclampsia include syncytiotrophoblast degeneration and increased intervillous thrombosis, as well as damage to the endothelium and thrombosis of villous blood vessels 37, 38 . Reduction in the levels of HCII in women with severe preeclampsia may contribute to development of these thrombotic lesions 16 . The situation may be analogous to that of mice with HCII deficiency, in which thrombosis following injury to the carotid arterial endothelium occurs more rapidly than in wild-type animals 39 .
Endogenous HCII antigen co-localized with DS in the walls of fetal blood vessels in the placental villi and potentially could be bound there in an activated state. HCII was also present in the syncytiotrophoblast layer, where it appeared to co-localize with HS.
The significance of this latter observation is unclear, since we could find no evidence of activation of HCII by placental HS. One possibility is that HS concentrates HCII at the syncytiotrophoblast surface, where it would be readily available to interact with DS in the stroma and inhibit thrombin following trophoblast injury. Relatively little HCII was detectable in the villous stroma, suggesting that the inhibitor is not present in this location in the normal term placenta.
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In summary, our data suggest that DS is the major anticoagulant GAG in the human placenta at term. In addition, placental DS contains disaccharide subunits known to interact with HCII and stimulates thrombin inhibition by HCII in vitro.
Immunohistochemical studies suggest that DS is positioned to activate HCII in the fetal blood vessels or in the stroma of placental villi after injury to the syncytiotrophoblast layer. Thus, HCII may serve to inhibit fibrin generation in the placenta. The papain extract was subjected to chromatography on a Mono Q column as shown in Fig. 1 . Peaks II and III were each treated sequentially with nitrous acid, chondroitin AC II-lyase, and chondroitin ABC-lyase. The material was dialyzed after each step, and the amount of GAG was determined by carbazole assay for uronic acid. Relative HCII activity is defined as the ability of each fraction to stimulate the thrombin-HCII reaction relative to that of porcine mucosal DS (e.g., the papain extract had 19.6% of the activity of an equal amount of porcine mucosal DS by weight).
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